Early Look at Gilead Sciences' Experimental Coronavirus Treatment Disappoints

A leading medical journal recently published an analysis of coronavirus patients treated with remdesivir, an experimental antiviral from Gilead Sciences (NASDAQ:GILD). While the data doesn't tell us much that we didn't know already, it did pour cold water on any lofty expectations and highlight reasons drug developers generally avoid compassionate use programs.